Theriva Biologics, Inc. (TOVX) intrinsic value & 10-year financials
Theriva Biologics, Inc. (TOVX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.21
- Market cap
- $2.5M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -374.6%
- Free cash flow (FY2025)
- -$16.7M
TOVX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$23.7M | -$2.08 | -$16.7M | — | -371.7% |
| FY2024 | — | -$25.7M | -$2.11 | -$16.9M | — | -220.7% |
| FY2023 | — | -$18.3M | -$0.13 | -$19.2M | — | -145.9% |
| FY2022 | — | -$19.7M | -$0.15 | -$19.2M | — | -366.1% |
| FY2021 | — | -$14.3M | -$0.02 | -$12.9M | — | 252.1% |
| FY2020 | — | -$10.0M | -$0.07 | -$12.2M | — | 86.3% |
| FY2019 | — | -$15.3M | — | -$13.9M | — | 127.3% |
| FY2018 | — | -$13.4M | — | -$17.3M | — | 148.3% |
| FY2017 | — | -$15.2M | — | -$20.4M | — | -2235.1% |
| FY2016 | — | -$27.3M | — | -$28.5M | — | -1020.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Theriva Biologics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Theriva Biologics, Inc. has earned high returns on invested capital, averaging 17.6% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Theriva Biologics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Theriva Biologics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.